The most common grade 3 or worse adverse events were QTc prolongation ( ten [ 14 % ] of 73 patients in the vandetanib group vs none in the placebo group ) , diarrhoea ( seven [ 10 % ] vs none ) , asthenia ( five [ 7 % ] vs three [ 4 % ] ) , and fatigue ( four [ 5 % ] vs none ) .
